Discover Clearwater Paper's Q4 2024 performance and strategic transformation. Learn about cost-saving measures, market trends, and projections for 2025.

Health systems are facing hurdles to implementing new and effective metastatic urothelial carcinoma (mUC) therapies into ...

Joshua Spector, UBS Securities, inquired about the timing and reliance of the cost improvement program. CEO Romano clarified that the $125 million to $175 million target is primarily cost-driven and ...